PAVmed (NASDAQ:PAVM) had its price target lowered by analysts at Ascendiant Capital Markets from $20.00 to $17.00. They now have a "buy" rating on the stock.
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
PAVmed (NASDAQ:PAVM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]